EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making

Lilia Bardoscia, Federico Camilli, Luca Triggiani, Elisa Ciurlia, Federico Iori, Eleonora Festa, Marco Trovò, Andrea Lancia iD, Beatrice Detti, Gianluca Ingrosso iD

Expert Review of Clinical Pharmacology · 2026

DOI: 10.1080/17512433.2026.2677891 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Lilia Bardoscia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Unit of Prato, Azienda USL Centro Toscana, Prato, Italy. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 126 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Prostate cancer is well known to be androgen-dependent, with growth directly relying on the androgen receptor signaling pathway. In fact, androgen deprivation therapy, with or without Docetaxel and/or newer hormonal drugs such as Abiraterone acetate, Enzalutamide, Apalutamide, and Darolutamide, remains the most effective systemic treatment for metastatic disease. Beyond PSA detection, there is a lack of standardized biohumoral markers to understand the biology of metastatic castrate-sensitive prostate cancer (mCSPC), predict response to newer therapies such as immunotherapy, and identify a true oligometastatic state. AREAS COVERED: A comprehensive, non-systematic literature review across Scopus, Google Scholar, Medline, EMBASE, and the Cochrane Library was conducted. New evidence was identified, gathered, and screened for relevance, limited to English-language publications. Information and recommendations on the emerging mCSPC biomarkers, their possible integration, and application for care decisions were evaluated. Our work aimed to summarize the current understanding of molecular characterization of mCSPC and the evidence on the role of emerging molecular biomarkers in guiding personalized treatment for mCSPC. EXPERT OPINION: The integration of data extracted from imaging with the molecular and genetic profiles of a specific tissue, using artificial intelligence, will help assess the genetic and biochemical makeup of living tissue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorProstatic Neoplasms, Castration-ResistantHumansMalePrecision MedicineClinical Decision-MakingAndrogen AntagonistsImmunotherapyNeoplasm MetastasisProstate-Specific AntigenAntineoplastic Agents, Hormonal

Stichwörter der Autor:innen

PTEN, BRCA1/2Prostate cancerTP53androgen deprivationdamage DNA repairmetastatic castrate-sensitive prostate cancerprostate-specific antigen (PSA)theranostics

Substanzen

Biomarkers, TumorAndrogen AntagonistsProstate-Specific AntigenAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Radiation Oncology Unit of Prato, Azienda USL Centro Toscana, Prato, Italy.
  • Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, Italy.
  • Radiation Oncology Department, University and Spedali Civili of Brescia, Brescia, Italy.
  • Radiation Oncology Unit, Vito Fazzi Hospital, Lecce, Italy.
  • Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Radiation Oncology, ASUFC "Santa Maria della Misericordia", Udine, Italy.

ORCID-Profile: Andrea Lancia, Gianluca Ingrosso

Zitieren

APA

Bardoscia, L., Camilli, F., Triggiani, L., Ciurlia, E., Iori, F., Festa, E., Trovò, M., Lancia, A., Detti, B., & Ingrosso, G. (2026). Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2677891

Vancouver

Bardoscia L, Camilli F, Triggiani L, Ciurlia E, Iori F, Festa E, et al. Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2677891

BibTeX
@article{Bardoscia2026,
  author = {Bardoscia, Lilia and Camilli, Federico and Triggiani, Luca and Ciurlia, Elisa and Iori, Federico and Festa, Eleonora and Trovò, Marco and Lancia, Andrea and Detti, Beatrice and Ingrosso, Gianluca},
  title = {Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  doi = {10.1080/17512433.2026.2677891}
}
Kostenlos starten →